Overview

Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC

Status:
Recruiting

Trial end date:
2025-02-04

Target enrollment:

Participant gender:

Summary

To Study Perioperative PD-1 Inhibitor and Cesium-131 Interstitial Brachytherapy in patients with locally recurrent HNSCC eligible for salvage surgery.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Cincinnati

Collaborator:

IsoRay Medical, Inc.

Treatments:

Pembrolizumab